Extra-hepatic replication and infection of hepatitis E virus in neuronal-derived cells

Journal of Viral Hepatitis

Volumn 23, Issue 7, 2016, Pages 512-521

  Drave, S A ^a   Debing, Y ^b   Walter, S ^a   Todt, D ^a   Engelmann, M ^a   Friesland, M ^a   Wedemeyer, H ^c   Neyts, J ^b   Behrendt, P ^a,c   Steinmann, E ^a  

^a INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

extra hepatic manifestation; Hepatitis E Virus (HEV); neurologic disorders; neuronal derived cells; ribavirin; viral replication

Indexed keywords

VIRUS RNA;

ARTICLE; ASTROCYTOMA CELL; CONTROLLED STUDY; DESMOPLASTIC CEREBELLAR MEDULLOBLASTOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE DOSAGE; GLIOBLASTOMA; HEPATITIS E; HEPATITIS E VIRUS; HUMAN; HUMAN CELL; LIFE CYCLE; NERVE CELL; NEUROEPITHELIOMA; NONHUMAN; OLIGODENDROGLIOMA; PRIORITY JOURNAL; RNA REPLICATION; VIRAL LIFE CYCLE; VIRAL TROPISM; VIRUS ASSEMBLY; VIRUS CAPSID; VIRUS ENTRY; VIRUS RELEASE; VIRUS REPLICATION;

EID: 84975129119     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12515     Document Type: Article

References (34)

1. http://www.ictvonline.org.
2. Cao D, Meng XJ. Molecular biology and replication of hepatitis E virus. Emerg Microbes Infect 2012; 1(8): e17.
3. Behrendt P, Steinmann E, Manns MP, Wedemeyer H. The impact of hepatitis E in the liver transplant setting. J Hepatol 2014; 61(6): 1418–1429.
4. Sayed IM, Vercouter AS, Abdelwahab SF, Vercauteren K, Meuleman P. Is HEV an emerging problem in industrialized countries? Hepatology 2015; 62(6): 1883–1892.
5. Wedemeyer H, Pischke S, Manns MP. Pathogenesis and treatment of hepatitis e virus infection. Gastroenterology 2012; 142(6): 1388–1397.
6. Kamar N, Dalton HR, Abravanel F, Izopet J. Hepatitis E virus infection. Clin Microbiol Rev 2014; 27(1): 116–138.
7. Kamar N, Garrouste C, Haagsma EB, Garrigue V, Pischke S, Chauvet C, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology 2011; 140(5): 1481–1489.
8. Kamar N, Izopet J, Tripon S, Bismuth M, Hillaire S, Dumortier J, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med 2014; 370(12): 1111–1120.
9. Pischke S, Stiefel P, Franz B, Bremer B, Suneetha PV, Heim A, et al. Chronic hepatitis e in heart transplant recipients. Am J Transplant 2012; 12(11): 3128–3133.
10. Gerolami R, Borentain P, Raissouni F, Motte A, Solas C, Colson P. Treatment of severe acute hepatitis E by ribavirin. J Clin Virol 2011; 52(1): 60–62.
11. Pischke S, Hardtke S, Bode U, Birkner S, Chatzikyrkou C, Kauffmann W, et al. Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. Liver Int 2013; 33(5): 722–726.
12. Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010; 376(9744): 895–902.
13. Bazerbachi F, Haffar S, Garg SK, Lake JR. Extra-hepatic manifestations associated with hepatitis E virus infection: a comprehensive review of the literature. Gastroenterol Rep 2015; epub ahead of print.
14. Dartevel A, Colombe B, Bosseray A, Larrat S, Sarrot-Reynauld F, Belbezier A, et al. Hepatitis E and neuralgic amyotrophy: Five cases and review of literature. J Clin Virol 2015; 69: 156–164.
15. Kamar N, Bendall RP, Peron JM, Cintas P, Prudhomme L, Mansuy JM, et al. Hepatitis E virus and neurologic disorders. Emerg Infect Dis 2011; 17(2): 173–179.
16. Woolson KL, Forbes A, Vine L, Beynon L, McElhinney L, Panayi V, et al. Extra-hepatic manifestations of autochthonous hepatitis E infection. Aliment Pharmacol Ther 2014; 40(11–12): 1282–1291.
17. van den Berg B, van der Eijk AA, Pas SD, Hunter JG, Madden RG, Tio-Gillen AP, et al. Guillain-Barre syndrome associated with preceding hepatitis E virus infection. Neurology 2014; 82(6): 491–497.
18. van Eijk JJ, Madden RG, van der Eijk AA, Hunter JG, Reimerink JH, Bendall RP, et al. Neuralgic amyotrophy and hepatitis E virus infection. Neurology 2014; 82(6): 498–503.
19. Geurtsvankessel CH, Islam Z, Mohammad QD, Jacobs BC, Endtz HP, Osterhaus AD. Hepatitis E and Guillain-Barre syndrome. Clin Infect Dis 2013; 57(9): 1369–1370.
20. Yazaki Y, Sugawara K, Honda M, Ohnishi H, Nagashima S, Takahashi M, et al. Characteristics of 20 Patients with Autochthonous Acute Hepatitis E in Hokkaido, Japan: First Report of Bilateral Facial Palsy Following the Infection with Genotype 4 Hepatitis E Virus. Tohoku J Exp Med 2015; 236(4): 263–271.
21. Despierres LA, Kaphan E, Attarian S, Cohen-Bacrie S, Pelletier J, Pouget J, et al. Neurologic disorders and hepatitis E, France, 2010. Emerg Infect Dis 2011; 17(8): 1510–1512.
22. Kamar N, Izopet J, Cintas P, Garrouste C, Uro-Coste E, Cointault O, et al. Hepatitis E virus-induced neurological symptoms in a kidney-transplant patient with chronic hepatitis. Am J Transplant 2010; 10(5): 1321–1324.
23. Nguyen HT, Shukla P, Torian U, Faulk K, Emerson SU. Hepatitis E virus genotype 1 infection of swine kidney cells in vitro is inhibited at multiple levels. J Virol 2014; 88(2): 868–877.
24. Shukla P, Nguyen HT, Faulk K, Mather K, Torian U, Engle RE, et al. Adaptation of a genotype 3 hepatitis E virus to efficient growth in cell culture depends on an inserted human gene segment acquired by recombination. J Virol 2012; 86(10): 5697–5707.
25. Shukla P, Nguyen HT, Torian U, Engle RE, Faulk K, Dalton HR, et al. Cross-species infections of cultured cells by hepatitis E virus and discovery of an infectious virus-host recombinant. Proc Natl Acad Sci U S A 2011; 108(6): 2438–2443.
26. Debing Y, Emerson SU, Wang Y, Pan Q, Balzarini J, Dallmeier K, et al. Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon. Antimicrob Agents Chemother 2014; 58(1): 267–273.
27. Koutsoudakis G, Kaul A, Steinmann E, Kallis S, Lohmann V, Pietschmann T, et al. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol 2006; 80(11): 5308–5320.
28. Zhou X, Wang Y, Metselaar HJ, Janssen HL, Peppelenbosch MP, Pan Q. Rapamycin and everolimus facilitate hepatitis E virus replication: revealing a basal defense mechanism of PI3K-PKB-mTOR pathway. J Hepatol 2014; 61(4): 746–754.
29. Goel A, Gupta N, Kalita J, Munjal S, Ranjan A, Misra U, et al. Hepatitis E virus unlikely to be the cause of neurological disease in a genotype 1 endemic region. J Viral Hepatitis 2015;22: (Suppl. 2): 126.
30. McLaurin J, Trudel GC, Shaw IT, Antel JP, Cashman NR. A human glial hybrid cell line differentially expressing genes subserving oligodendrocyte and astrocyte phenotype. J Neurobiol 1995; 26(2): 283–293.
31. Hughes RA, Cornblath DR. Guillain-Barre syndrome. Lancet 2005; 366(9497): 1653–1666.
32. Lehmann HC, Hartung HP, Kieseier BC, Hughes RA. Guillain-Barre syndrome after exposure to influenza virus. Lancet Infect Dis 2010; 10(9): 643–651.
33. Schlosser J, Eiden M, Vina-Rodriguez A, Fast C, Dremsek P, Lange E, et al. Natural and experimental hepatitis E virus genotype 3-infection in European wild boar is transmissible to domestic pigs. Vet Res. 2014;45: 121-014-0121-8.
34. Han J, Lei Y, Liu L, Liu P, Xia J, Zhang Y, et al. SPF rabbits infected with rabbit hepatitis E virus isolate experimentally showing the chronicity of hepatitis. PLoS ONE 2014; 9(6): e99861.